E. Thervet, M. Loriot, and S. Barbier, Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing, Clinical Pharmacology & Therapeutics, vol.87, issue.6, p.721, 2010.
DOI : 10.1097/00007890-200212150-00002

I. Macphee and D. Holt, A Pharmacogenetic Strategy for Immunosuppression Based on the CYP3A5 Genotype, Transplantation, vol.85, issue.2, p.163, 2008.
DOI : 10.1097/TP.0b013e3181609054

D. Anglicheau, L. Corre, D. Lechaton, and S. , Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy, American Journal of Transplantation, vol.8, issue.3, p.595, 2005.
DOI : 10.1177/0091270003043006001

L. Meur, Y. Djebli, N. Szelag, and J. , CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients, Clinical Pharmacology & Therapeutics, vol.80, issue.1, 2006.
DOI : 10.1016/j.clpt.2006.03.012

M. Mourad, G. Mourad, and P. Wallemacq, Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids, Transplantation, vol.80, issue.7, p.977, 2005.
DOI : 10.1097/01.TP.0000174131.47469.D2

D. Kniepeiss, W. Renner, and O. Trummer, The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation, Clinical Transplantation, vol.8, issue.1, 2009.
DOI : 10.1111/j.1399-0012.2009.01198.x

P. Kuehl, J. Zhang, and Y. Lin, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nature Genetics, vol.27, issue.4, p.383, 2001.
DOI : 10.1038/86882

V. Haufroid, P. Wallemacq, and V. Vankerckhove, CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study, American Journal of Transplantation, vol.41, issue.11, p.2706, 2006.
DOI : 10.1073/pnas.050585397

I. Macphee, S. Fredericks, and M. M. , Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians, Transplantation, vol.79, issue.4, p.499, 2005.
DOI : 10.1097/01.TP.0000151766.73249.12

N. Tsuchiya, S. Satoh, and H. Tada, Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients, Transplantation, vol.78, issue.8, p.1182, 2004.
DOI : 10.1097/01.TP.0000137789.58694.B4

N. Picard, N. Djebli, F. Sauvage, and P. Marquet, Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5, Drug Metabolism and Disposition, vol.35, issue.3, p.350, 2007.
DOI : 10.1124/dmd.106.012161

A. Daly, Pharmacogenetics and human genetic polymorphisms, Biochemical Journal, vol.1770, issue.3, p.435, 2010.
DOI : 10.1097/00130832-200410000-00013

M. Miura, H. Kagaya, and S. Satoh, Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients, Therapeutic Drug Monitoring, vol.30, issue.5, p.559, 2008.
DOI : 10.1097/FTD.0b013e3181838063

K. Benkali, A. Premaud, and N. Picard, Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients, Clinical Pharmacokinetics, vol.76, issue.8, p.805, 2009.
DOI : 10.2165/11318080-000000000-00000
URL : https://hal.archives-ouvertes.fr/hal-01390737

N. Picard, T. Cresteil, A. Premaud, and P. Marquet, Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5, Therapeutic Drug Monitoring, vol.26, issue.6, p.600, 2004.
DOI : 10.1097/00007691-200412000-00004

R. Obach, Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes, Drug Metab Dispos, vol.27, issue.11, p.1350, 1999.

K. Venkatakrishnan, L. Von-moltke, and D. Greenblatt, Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate, J Pharmacol Exp Ther, vol.297, issue.1, p.326, 2001.